Pfizer makes small pipeline changes in first-quarter update

Pfiz­er trimmed a hand­ful of pro­grams from its pipeline Wednes­day morn­ing as part of its first-quar­ter earn­ings up­date.

The com­pa­ny dis­con­tin­ued de­vel­op­ment of VTX-801, a re­com­bi­nant AAV gene ther­a­py for the rare in­her­it­ed dis­or­der Wil­son’s dis­ease that was be­ing de­vel­oped with Vivet Ther­a­peu­tics. Pfiz­er had ac­quired a mi­nor­i­ty stake in Vivet in March 2019 and was man­u­fac­tur­ing the ther­a­py’s vec­tor for a Phase 1/2 study.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.